Arcutis Biotherapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
ARQT$27.39+4.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(129,251) | $(195,856) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 495 | 573 |
| Non-cash lease expense | 301 | 266 |
| Amortization of intangible assets | 1,646 | 563 |
| Net accretion on marketable securities | (5,805) | (5,517) |
| Non-cash interest expense | 2,809 | 3,014 |
| Stock-based compensation expense | 32,337 | 30,056 |
| Changes in fair value of embedded derivative instrument | (429) | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (33,133) | (10,959) |
| Inventories | (135) | (6,399) |
| Prepaid expenses and other current assets | (882) | (10,087) |
| Accounts payable | 2,334 | 4,345 |
| Accrued liabilities | 18,850 | (323) |
| Operating lease liabilities | (547) | (489) |
| Net cash used in operating activities | (111,410) | (190,813) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of marketable securities | (237,421) | (107,660) |
| Proceeds from maturities of marketable securities | 231,507 | 350,500 |
| Purchases of property and equipment | (143) | (422) |
| Net cash (used in) provided by investing activities | (6,057) | 242,418 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from issuance of common stock upon exercise of stock options | 1,282 | 1,041 |
| Proceeds from issuance of common stock pursuant to employee stock purchase plan | 649 | 993 |
| Proceeds from issuance of common stock, net of issuance costs | 161,682 | — |
| Net cash provided by financing activities | 163,613 | 2,034 |
| Effect of exchange rate changes on cash | (1) | (118) |
| Net increase in cash, cash equivalents, and restricted cash | 46,145 | 53,521 |
| Cash, cash equivalents, and restricted cash at beginning of period | 89,323 | 54,875 |
| Cash, cash equivalents, and restricted cash at end of period | $135,468 | $108,396 |
| SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION: | ||
| Milestone for intangible asset not yet paid in cash | $5,000 | $— |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||
| Interest expense paid in cash | $19,253 | $18,862 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.